Secondary Progressive Multiple Sclerosis (SPMS) Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

Secondary Progressive Multiple Sclerosis (SPMS) Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

  • Transparency Market Research
  • Ongoing
  • Pharmaceutical

Report Description

1
1

Multiple sclerosis (MS), which is also known as disseminated sclerosis, is an inflammatory disease of the nervous system. It is primarily characterized by the disruption of the nerve cells of the spinal cord and the brain, which results in the loss of ability to communicate along with various other physical, mental, and psychiatric problems. Secondary progressive multiple sclerosis (SPMS) is a type of MS that typically follows relapsing-remitting MS (RRMS). Approximately 65% patients with relapsing-remitting MS develop SPMS. Secondary progressive multiple sclerosis is difficult to diagnosis for neurologists due to progression. Repeated MRI scanning of the brain and neurological examinations are used to diagnose SPMS. Fatigue, depression, and problems thinking, stiffening or tightening of leg muscles, bowel and bladder problems, and trouble with coordination are key sign and symptoms of secondary progressive multiple sclerosis.

Increasing prevalence of neurological disorders, rising demand for advanced therapeutics for the treatment of SPMS in developing nations are some major factors driving the market. Multiple sclerosis is the most widespread neurological disorder that can affect individuals at any age; however, it is mainly diagnosed people between the ages of 20 and 40. According to Multiple Sclerosis Foundation, there are more than 2.5 million people suffering from multiple sclerosis around the world in 2015.

The global secondary progressive multiple sclerosis (SPMS) treatment market can be segmented based on medical treatment, end-user, and region. In terms of medical treatment, the market can be categorized into exercise, psychotherapy, and medication. Medicines including Interferon beta (Avonex, Betaseron, Extavia, Plegridy, and Rebif), Teriflunomide (Aubagio), Dimethyl fumarate (Tecfidera), Alemtuzumab (Lemtrada), Fingolimod (Gilenya), and Natalizumab (Tysabri) can help control secondary progressive multiple sclerosis.

In terms of end-user, the global secondary progressive multiple sclerosis (SPMS) treatment market can be classified into hospitals, clinics, and others. In term of revenue, the hospitals segment accounted for a significant share of the market in 2016.

Based on geography, the global secondary progressive multiple sclerosis (SPMS) treatment market can be segregated into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. These regions can be further divided into countries and medical treatment. North America is the leading market for SPMS treatment. In terms of revenue, the U.S. holds a major share of the market in North America. The market in Europe is expanding at a considerable pace due to the rise in prevalence of SPMS in the region. The market in Asia Pacific and Latin America is projected to expand significantly in the near future due to high annual incidence of secondary progressive multiple sclerosis. Developing economies such as China and India are anticipated to contribute to the expansion of the market in Asia Pacific between 2017 and 2025 due to better health care infrastructure, economic growth, increase in the number of insurance payers, growth of the private health care sector, and increase in awareness regarding disease. Brazil and Mexico dominate the secondary progressive multiple sclerosis treatment market in Latin America. South Africa, Turkey, and other developing countries in Middle East & Africa are the major markets for secondary progressive multiple sclerosis (SPMS) treatment.

Key players operating in the global secondary progressive multiple sclerosis (SPMS) treatment market are  Pfizer INC, Bayer HealthCare AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Novartis AG, Biogen, Inc., Sanofi S.A., Synthetic Biologics, Inc. and Active Biotech AB.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Have query on this report?

Make an Enquiry

Success Stories

Our Clients

Tell Us What You Need and We’ll Get Back with the Best Solutions Available.

*
*
*

get in touch

Location :

State Tower, 90 State Street, Suite 700, Albany NY - 12207, United States

Call Us :

US/Canada toll free : 866-997-4948

Tel : +1-518-621-2074